Deep Track Capital, LP: OCULAR THERAPEUTIX INC (OCUL): Quarterly 13F Position History
As of Q2 2026, Deep Track Capital, LP reported 19,686,282 shares of OCULAR THERAPEUTIX INC (OCUL), worth $193.3M and representing 2.8% of its 13F equity book. The position first appeared in Q4 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 19,686,282Shares Held (Latest Filing)
- $193.3MReported Market Value (Latest Filing)
- 2.8%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$26.6MQuarter-over-Quarter Value Change
- 19,686,282Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 19,686,282 | 0 | – | $193.3M | 2.8% | $9.8 |
| Q1 2026 | 19,686,282 | +11,615,868 | +143.9% | $166.7M | 3.4% | $8.5 |
| Q4 2025 | 8,070,414 | 3,861,723 | -32.4% | $98.0M | 2.2% | $12.1 |
| Q3 2025 | 11,932,137 | 2,362,283 | -16.5% | $139.5M | 3.9% | $11.7 |
| Q2 2025 | 14,294,420 | 0 | – | $132.7M | 4.3% | $9.3 |
| Q1 2025 | 14,294,420 | +1,458,138 | +11.4% | $104.8M | 3.4% | $7.3 |
| Q4 2024 | 12,836,282 | +114,822 | +0.9% | $109.6M | 4.1% | $8.5 |
| Q3 2024 | 12,721,460 | 0 | – | $110.7M | 3.5% | $8.7 |
| Q2 2024 | 12,721,460 | 0 | – | $87.0M | 2.6% | $6.8 |
| Q1 2024 | 12,721,460 | +3,490,691 | +37.8% | $115.8M | 3.3% | $9.1 |
| Q4 2023 | 9,230,769 | – | – | $41.2M | 1.4% | $4.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Deep Track Capital, LP first disclose a OCUL position in 13F-HR filings?
Deep Track Capital, LP first reported OCULAR THERAPEUTIX INC (OCUL) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Deep Track Capital, LP's most recent quarter-over-quarter share-count change in OCUL?
Deep Track Capital, LP held the same 19,686,282 shares of OCUL between Q1 2026 and Q2 2026, so the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Deep Track Capital, LP's cost basis in OCUL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.